NASDAQ · Biotechnology

Ensysce Biosciences, Inc. (ENSC) Stock

$0.26 -1.95% NASDAQ: ENSC Healthcare

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.

Valuation

MetricValue
Price$0.26
Market Cap$2.38M
P/E Ratio-0.08
P/B Ratio-5.26
P/S Ratio1.67
EPS (TTM)$-3.98
52-Week High$2.75
52-Week Low$0.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-631.47%
ROA-543.71%
ROCE-500.00%
Gross Margin-72.88%
Operating Margin-4.19%
Net Margin-810.57%
Debt/Equity-0.72
Current Ratio1.59

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$3.0M$2.0M$5.0M$5.0M
Operating Profit$-20.0M$-24.0M$-11.0M$-7.0M$-10.0M
Net Profit$-29.0M$-24.0M$-11.0M$-8.0M$-10.0M
EPS$-355.68$-139.44$-4.69$-4.57$-3.98
Op Margin-562.7%-959.9%-480.4%-129.2%-202.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$6.0M$3.0M$6.0M$7.0M
Total Liabilities$25.0M$10.0M$3.0M$2.0M$5.0M
Cash$12.0M$3.0M$1.0M$4.0M$4.0M
Borrowings$17.0M$4.0M$1.0M$0$306.7B

Latest News

Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development InvestorsHub · Jul 14, 2026 Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant ACCESS Newswire · Jul 14, 2026 ENSC Receives Vital Funding for Drive to Commercialization Zacks Small Cap Research · Jul 14, 2026 Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth GlobeNewswire · Jul 13, 2026 Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-18.0M$-11.0M$-7.50T$-7.81T
Investing Cash Flow$0$0$0$0$-123.6B
Financing Cash Flow$0$-1.0M$-1.0M$9.88T$8.74T
Net Cash Flow$12.0M$-9.0M$-2.0M$2.38T$808.3B
Free Cash Flow$-8.0M$-18.0M$-11.0M$-7.50T$-7.81T

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.24
FCF Yield-328284435.25%
Quick Ratio1.40
Interest Coverage-628.42
Return 1Y-86.19%
Return 3Y-99.01%
Return 5Y-100.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIM $0.24 -5.84% -0.09 $801193 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
KALA $0.76 +3.59% -0.76 $14.62M 0.00%
KZIAKazia Therapeutics Ltd ADR $14.54 +2.76% -2.01 $23.55M 0.00%
OGEN $0.50 -1.96% -0.14 $2.26M 0.00%

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

Ensysce Biosciences, Inc. is led by CEO D. Lynn Kirkpatrick, employs 7 people, headquartered in US, publicly traded since 2018.

Ensysce Biosciences, Inc. (ENSC) stock trades at $0.26 with a market capitalization of $2.38M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of -5.26, price-to-sales of 1.67. Over the past 52 weeks the stock has ranged between $0.23 and $2.75, and currently trades 90.5% below its 52-week high.

On profitability, Ensysce Biosciences, Inc. generates a return on equity (ROE) of -631.47%, return on capital employed of -500.00%, an operating margin of -4.19%, a net profit margin of -810.57%.

Official website: www.ensysce.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides